Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for KalVista Pharmaceuticals (KALV) over the last 1 years, with Oct 2024 value amounting to $46.7 million.

  • KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) rose 35.09% to $46.7 million in Q4 2024 from the same period last year, while for Oct 2024 it was $46.7 million, marking a year-over-year increase of 35.09%. This contributed to the annual value of $36.8 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) is $46.7 million, which was up 1.00% from $46.2 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $46.7 million during Q4 2024, with a 5-year trough of $17.7 million in Q2 2020.
  • For the 2-year period, KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $38.9 million, with its median value being $35.8 million (2024).
  • Data for KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 35.09% (in 2024) over the last 5 years.
  • Over the past 3 years, KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $17.7 million in 2020, then reached $34.6 million in 2023, then soared by 35.09% to $46.7 million in 2024.
  • Its Shares Outstanding (Diluted Average) stands at $46.7 million for Q4 2024, versus $46.2 million for Q3 2024 and $36.8 million for Q2 2024.